Ahmed Abd El Halim

• Leading and development for team members.
• Managing sales team and distributor.
• Responsible for launch and prelaunch activities for 6 brands (Sleep Apnea Implant Genio- RDS- cystic fibrosis CFTR modulators- AGVHD Remestemcel)
• KOLs engagement
• Prepare the access dossier with regulatory and access team
• Pricing and value dossier presentation to concerned specialty.
• External stakeholders engagement
• Profitability management across existing portfolio (Cardiovascular-urology-Anesthesia- Oncology- Gynecology-Surgery) and pre-launched therapy areas.
• Leading branded generic portfolio for Anti-infectives- Anti-emetics- Oncology-fertility) across private and tender business
• Coordinate with Marketing, Medical and regulator departments for the pre-launch activities.

Hierarchy:

• Reporting to BUH-GENMED GULF.
• Direct report a team with 9 senior product specialists across Kuwait, Qatar and Bahrain
• Responsible for Cardiology-Endocrinology-Bone- Immunology(Rheuma-Derma-GIT)

Achievement:

• Restructuring and development of Cardiovascular REPATHA team in Kuwait resulting in achieving double digit growth with 80% MS across 2021 , 2022 and 2023.
• Introduction of Repatha the only PCSK9 in Hamad general hospital with endocrine department.
• Introduction of Prolia through diabetes (KDS) and endocrinologists as the first biologic in Kuwait PHCs raising MS% from 65% to 78% in one year.
• Restructuring and development of Bone/Immunology team across Kuwait and Qatar with the inclusion of 2 brands (Amgevita and Evenity)
• Introduction of the first biosimilar in Kuwait MOH through collaborative efforts between crossfunctions and external stakeholders
• All changes resulted in increasing the turnover of Kuwait and Qatar from 11 M$ 2021 to 16 M$ 2022 and 20 M$ 2023.
• Responsible for managing 3 launches (Prolia in Primary care- Amgevita- Evenity) across 2 countries

Team Development:

• Tailored career development plan CDP per each member.
• Enrolment of different members in championship role across different functions for one year with rotation.
• Championship program resulted in promoting MSL Upper gulf from my team.
• 3 Upper Gulf Best achievers were nominated from my team members during championship.
• Close follow up with crossfunction monitoring their progress.

Distributor, CMS and external stakeholders management:

• Distributor management, Forecasting, Bidding and Expiry management
• Handling Al Homaizi Kuwait - Doha Drug store Qatar- City pharmacy Bahrain Amgen business relation (Forecast-stock-expiry-orders-delivery).
• Contracts follow-up and delivery to CMS-HMC and Salmanyia.
• Crossfunctional collaboration with regulatory department.
• Work closely and direct management of internal medicine committee, Kuwait Heart association (Dr Mohamed Al Jarallah)- Kuwait and Qatar Diabetes society- KOPS- KAR - Primary Care - Kidney and transplantation society (Dr Turki Al otaibi) for Amgen related products (Introductions- approvals-projects).

Responsibilities

• Develop business plans for their geography and implement national sales strategies and programs.
• Promoted product promotions, sales and offers throughout interactions to increase order value and sales.
• Visited potential customers to build relationships and present sales pitches on products.
• Collaborate cross-functionally with other Amgen business units including District Sales Mangers, Regional Sales Directors and Corporate Account Managers.
• Team development and distributor management.

Hierarchy:

• Reporting to GCC country head
• Establishing and leading Oncology, Pain (Diabetic Neuropathy- Cancer, Non Cancer pain and respiratory sales team (2 sales supervisors-9 Product specialists- 2 Key Account Manager- Market access coordinator)

Achievements:

• Launch Mundipharma specialty care across 3 countries
• Successful 14 launches per country and per brand to achieve ITM & market penetration objectives.
• Team building across 3 countries and attracting the right talents
• Growing business from 150 K$ 2014 to 15 M$ in 2020.

Team Development:

• Tailored Accelerated Mundipharma development plan.
• Enrolment of different members in assignment role across different functions for one year with rotation.
• Promotion of 2 sales supervisors, MSL, Market access lead, brand manager, compliance coordinator and 2 KAMs
• Nomination of MEA best achievers yearly from Upper Gulf team
• Close follow up with crossfunction monitoring their progress.

Distributor, CMS and external stakeholders management:

• Distributor management, Forecasting, Bidding and Expiry management
• Handling AlWazzan- Safwan- Al Baker Qatar- City Pharmacy Mundipharma business relation (Forecast-stock-expiry-orders- deliveries- contracts).
• Crossfunctional collaboration with regulatory department.
• Work closely with internal medicine committee, Kuwait diabetes society- KCC- Palliative care society for Mundipharma related products.

Responsibilities

• Initiating & coordinating development of action plans to penetrate new markets.
• Managing 14 launches per brand and per country
• Developing & maintaining strong business relationships with key opinion leaders and contacts with vendors and distributors
• Identifying & evaluating growth opportunities
• Managing distributors among 3 countries
• Full understanding of all relevant compliance rules, polices & processes
• Ensuring actions of self & team are fully compliant
• Ensure sales force KPIs for the teams are well met
• Recruitment and field force development through their preset Mundipharma accelerate performance annual review
• Ensuring marketing plans & strategies are implemented effectively in the assigned territory
• Budgeting, forecasting, supply & demand management, both OPEX management and allocation for upper gulf cluster.
• Distributor management, Forecasting, Bidding and Expiry management
• Driving Brand Performance through the cross-functional team through different tools (Internal workshops, performance dashboards) to maximize brand potential.

• Applied excellent negotiation, upselling and sales techniques to maximize revenue.
• Prepared and presented technical and commercial offers to clients based on company standards.
• Cultivated solid and loyal relationships with existing clients to deliver demand generation.
• Enlisting respiratory products in MOH and trade
• Development of marketing plan for respiratory products in Gulf region in cooperation with META Marketing director
• Sales performance management in upper gulf cluster
• Best Market access global 2015 Mundipharma
• Best Achiever MEA 2015
• Bahrain market penetration and introduction in institution
• Qatar market penetration and launching Mundipharma respiratory and Pain portfolio

2014 :

• Introduction of Flixotide nebules to 12 out of 12 of my polyclinics
• Introduction of Seretide inhaler in Sabah hospital
• I have been assigned with EMAP SVP (Rogerio Riberio), EMAP communication director (Christian Ball) & GSK global communication team to innovate solutions through digital marketing campaigns to ensure local alignment of the current strategy and GSK values across the whole EMAP especially the 5 pillars (Russia, Latin America, Asia Pacific, Middle East, Africa)
• Reporting to Kuwait Country manager as a key account manager.

2013: Senior medical representative

• GNE (Gulf & Near East) Premiere Award.
• 117% achievement.
• Flixotide nebules & Seretide 125/25 introduction in MOH.
• Starter Kit program for Asthmatics with Rashed Allergy center
• Compliance project with Rashed Allergy Center.
• Zero Reliever Project with Kuwait polyclinics.

2012:

• 104% Achievement & 27% growth over 2011 in tender .
• Raising sales of Flixotide Nebules to extent that trade accounts in my area almost 70% market share in nebulizer market which has the great impact on moving the ranking of Flixotide to number 6 in IMS
• Market building activities as national asthma campaign with Rashed Allergy Center and primary care.

2010 - 2011

• Gulf Champion 2010.
• Achieved 126% in 2010 and 104% in 2011 in both trade and tender.
• Introduction of formulas in new accounts.
• Introduction of Seretide 500 in MOH .
• Pediatric asthma workshops in coordination with Sabah Pediatric hospital to build up the pediatric asthma market.
• ntroduction of Seretide Evohaler to MOH and opening for expatriates.

• Cairo best achiever 2009
• A1 (growth), A1 (market share) in Diovan range.
• Introduction of Exforge in Egyptian TV clinic (Maspero).
• Achieving remarkable growth in most of potential accounts (Azhar University hospital,Maspero and Al Qobba Armed hospital).